Helicobacter pylori infection in children

Idalmis Aguilera Matos1, Sarah Esther Diaz Oliva1, Angel A Escobedo2

  • 1Pediatric Gastroenterology, Institute of Gastroenterology, Havana, Cuba.

BMJ Paediatrics Open
|August 21, 2020
PubMed

Insights

Helicobacter pylori infection is common globally, often asymptomatic in children. Treatment decisions for childhood H. pylori focus on specific benefits due to resistance and fewer complications.

Area of Science:

  • Pediatric Infectious Diseases
  • Gastroenterology
  • Microbiology

Background:

  • Helicobacter pylori infection is highly prevalent worldwide, typically acquired in childhood.
  • Associated with severe gastroduodenal conditions like ulcers, atrophy, and cancers.
  • High antimicrobial resistance complicates eradication efforts.

Purpose of the Study:

  • To review current considerations for diagnosing and treating H. pylori infection in children.
  • To emphasize outcomes and treatment strategies specific to pediatric cases.
  • To discuss the challenges posed by antimicrobial resistance in H. pylori eradication.

Main Methods:

  • This is a review article, synthesizing current knowledge on childhood H. pylori infection.
  • Focuses on epidemiological data, diagnostic approaches, and treatment regimens.
  • Examines outcomes and challenges in pediatric H. pylori management.

Main Results:

  • Childhood H. pylori infections are often asymptomatic with fewer complications than in adults.
  • Potential inverse relationships with allergic and inflammatory bowel diseases are under investigation.
  • Diagnosis and treatment in children are reserved for specific circumstances with clear benefits.

Conclusions:

  • The management of H. pylori in children requires careful consideration of risks, benefits, and antimicrobial resistance.
  • Further research into H. pylori's role in pediatric health, including its relationship with other diseases, is warranted.
  • Tailored treatment strategies are essential for effective H. pylori eradication in pediatric populations.

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
847
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
402
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
943
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
628
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.0K
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
1.7K